Matching articles for "cangrelor"
Issue 1593 · March 9, 2020 Free
Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors

Opioids delay gastric emptying and the absorption of many oral drugs, including the P2Y 12 inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) ,…

Med Lett Drugs Ther. 2020 Mar 9; 62(1593):40
Opioids delay gastric emptying and the absorption of many oral drugs, including the P2Y 12 inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) , which are commonly used for initial treatment of acute coronary syndrome (ACS). An article in our February 25, 2019 issue reviewed studies showing that coadministration of opioids delayed and decreased absorption of oral P2Y 12 inhibitors and increased platelet reactivity. Recently published clinical outcomes data may add to these concerns.
Issue 1566 · February 25, 2019
Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors

The FDA has required manufacturers of the oral P2Y 12 platelet inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) to warn in the product labels that…

Med Lett Drugs Ther. 2019 Feb 25; 61(1566):31-2
The FDA has required manufacturers of the oral P2Y 12 platelet inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) to warn in the product labels that the absorption of these drugs may be delayed or reduced when taken with an opioid agonist.
Issue 1480 · October 26, 2015
Cangrelor (Kengreal) - An IV Antiplatelet Drug for PCI

The FDA has approved cangrelor ( Kengreal – The Medicines Company), an IV P2Y12 platelet inhibitor, as an adjunct to percutaneous coronary intervention (PCI) in patients who have not been pretreated with a…

Med Lett Drugs Ther. 2015 Oct 26; 57(1480):145-6
The FDA has approved cangrelor ( Kengreal – The Medicines Company), an IV P2Y12 platelet inhibitor, as an adjunct to percutaneous coronary intervention (PCI) in patients who have not been pretreated with a P2Y12 inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.